Researcher Spotlight: Jamie Flerlage, MD
St. Jude Children’s Research Hospital, Inc.
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is a rare
subtype of Hodgkin lymphoma (HL) that tends to grow slower than HL and requires different treatment. Dr. Jamie Flerlage says, “while it is almost 100 percent curative, the treatment regimens utilized vary greatly in their toxicity, both short and long term, with little data to support the use of one regimen over another.”
By collaborating internationally, Dr. Flerlage hopes to generate statistically significant data to help better inform the treatment of this rare disease.
Her LRF research project’s focus is to reduce late side effects in HL survivors through novel frontline therapies.
Dr. Flerlage is an Assistant Member of the Leukemia/Lymphoma Division at St. Jude Children’s Research Hospital, Inc. She obtained her MD at Albany Medical College and is currently leading the St. Jude-Stanford-Dana Farber consortium to develop frontline treatment strategies. Dr. Flerlage’s hope for the future is to “be a leader in the field of pediatric Hodgkin lymphoma and continue to find novel ways to cure the disease with limited late effects.” She hopes to have a better understanding of the genetics of the disease and a better comprehension of the development of HL through learning the late effects of survivors.
Her passion for lymphoma research derives from a personal experience of watching a loved one’s journey with cancer. Dr. Flerlage says that this experience has kept her motivated and curious. “While this disease is curable, I will constantly ask how we can do it better all around the world,” she says.
The post Jamie Flerlage, MD appeared first on Lymphoma Research Foundation.
